A new study finds that hospice enrollment rates vary more by health center than individual patient characteristics. Additionally, a meta-analysis suggests that high processed meat consumption is associated with an increased risk of stomach cancer, while another study identifies a potential target for leukemia treatment and notes the pe...
SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateAug 1, 2006
Researchers found that STAT1 expression was lower in SCCHN tumors than in normal tissue, and increasing STAT1 expression led to suppressed tumor growth. The study also suggests that STAT1 works as a tumor suppressor for SCCHN cells, but when its expression is lowered, SCCHN tumors grow.
SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 31, 2006
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers create conditional mouse model to study CBFB-SMMHC, a fusion protein linked to 12% of human AML cases. The model shows that CBFB-SMMHC induces abnormal preleukemic blood cell progenitors, leading to AML development in adult mice.
A new clinical trial found that using minimal residual disease (MRD) measurements, doctors can accurately assess treatment response and adjust therapy, leading to a high remission rate and low treatment-related mortality. This breakthrough approach improved outcomes for pediatric AML patients by identifying slow responders and intensif...
SourceSt. Jude Children's Research Hospital·DateDec 13, 2005
Recent studies have shown that treatment of chronic myeloid leukemia has improved significantly, with a focus on reducing residual disease through continued therapy and new treatment options. These advances have led to better prognosis for patients, providing substantial prolongation of normal life.
SourceAmerican Society of Hematology·JournalBlood·DateDec 12, 2005
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Researchers at Ohio State University discovered a new gene marker, ERG, that signals an aggressive form of acute myeloid leukemia (AML) requiring intensive therapy. High ERG activity is associated with poor relapse and survival rates in AML patients with normal cytogenetics.
SourceOhio State University·JournalJournal of Clinical Oncology·DateNov 14, 2005
A study found that AML patients with the 8;21 translocation have a poor response to treatment and are more likely to relapse. Nonwhite patients with this abnormality were almost six times less likely to achieve complete remission than whites.
SourceOhio State University·JournalJournal of Clinical Oncology·DateSep 7, 2005
Researchers at Ludwig Maximillians University report that AML1-ETO cooperates with FLT3 to induce rapid and aggressive acute leukemia in mice. This study supports a pathogenetic model of acute leukemia, which requires activating mutations in signal transduction pathways and transcription factors for leukemogenesis.
SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 14, 2005
New research presented at the American Society of Hematology Annual Meeting reveals promising results for tipifarnib, a potential treatment for acute myeloid leukemia (AML) in elderly patients. The study found molecular predictors of response to tipifarnib, offering hope for improved patient outcomes.
Researchers have successfully demonstrated that half-matched donor (haploidentical) natural killer cells can survive and persist to actively attack cancer cells, potentially leading to remission and eligibility for bone marrow transplant. This breakthrough treatment option shows promise for some patients with AML.
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Research suggests that more intense therapies lead to better remission rates and longer survival for adults with acute myeloid leukemia (AML) who have normal genetic makeup. Patients with an enlarged spleen are less likely to enter remission, highlighting the need for targeted treatment.
SourceOhio State University·JournalJournal of Clinical Oncology·DateNov 29, 2004
A recent study published in Cancer Epidemiology, Biomarkers and Prevention journal found that obesity is associated with a higher risk of acute myeloid leukemia (AML) in older women. The study followed over 37,000 Iowa women for 14 years and found that those who were overweight or obese had a 90% increased risk of developing AML compar...
A new analysis has found a link between breastfeeding and lower risks of both acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) in children. The study suggests that even short-term breastfeeding may be protective, particularly during the first few months.
SourceUniversity of California - Berkeley·JournalPublic Health Reports·DateOct 27, 2004
A recent study led by Dr. Ardeshir Ghavamzadeh and Dr. Kamran Alimoghaddam found that arsenic achieved complete remission in over 90% of newly diagnosed APL patients. The treatment has also shown promising results in other cancers like multiple myeloma, with a mean survival time of nearly 34 months for most patients.
SourceEuropean Organisation for Research and Treatment of Cancer·DateSep 29, 2004
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
A new study reveals gene microarray technology can accurately diagnose acute myeloid leukemia subtypes, leading to better treatments. The signatures of gene expression identified in pediatric leukemias also apply to adult cases, improving diagnosis and treatment outcomes.
SourceSt. Jude Children's Research Hospital·JournalBlood·DateJul 13, 2004
Researchers found that AML patients with abnormal chromosomes during remission are more likely to relapse and have a shorter survival. This suggests that routine testing for chromosomal abnormalities may be necessary to predict long-term outcomes in these patients.
SourceOhio State University·JournalJournal of Clinical Oncology·DateJun 16, 2004
A retrospective study of 110 elderly leukemia patients found similar complete remission and two-year survival rates as younger patients when treated with anthracyclin-based induction chemotherapy. The study's findings suggest that age is not a predictor of survival, but rather the treatment protocol received.
Researchers have identified two distinct patterns of gene activity that correlate with patient outcomes in intermediate-risk AML. The findings could lead to more personalized treatment approaches for patients with this type of cancer.
SourceStanford Medicine·JournalNew England Journal of Medicine·DateApr 14, 2004
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.
SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 16, 2004
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A recent study identified 35 genes that may be linked to prognosis in pediatric acute myeloid leukemia (AML), providing new insights into the disease. These unexpected genes were found independently of current classification methods and separated patients into high- and low-risk groups.
SourceAmerican Society of Hematology·JournalBlood·DateAug 25, 2003
Research suggests that a mutation in a tyrosine kinase receptor gene, when combined with aml1-eto gene mutation, can cause acute myeloid leukemia in mice. This discovery raises the possibility of new treatments targeting these genes to control the disease.
SourceWashU Medicine·JournalProceedings of the National Academy of Sciences·DateAug 1, 2003
Researchers induce leukemia cells to change behavior and stimulate immune system, killing significant numbers of leukemia cells in a 3-step process. The approach has shown strong killing effect against AML cell lines but not other types of cancer, with potential for safe transfer back into patients.
SourceUniversity of California - San Diego·JournalBiology of Blood and Marrow Transplantation·DateOct 21, 2002
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
Two new drugs, PKC412 and CT53518, have shown promising results in treating acute myeloid leukemia (AML), a deadly form of blood cancer. The drugs, which target the FLT3 receptor, have been effective in killing leukemia cells and prolonging survival in mouse models.
SourceHoward Hughes Medical Institute·JournalCancer Cell·DateJun 7, 2002
Researchers have developed a new drug, CEP-701, that targets the genetic error causing a type of leukemia. The drug has shown promising results in clinical trials, interfering with the signal of the altered gene and leading to leukemia cell death.
The European Commission has designated Mylotarg as an orphan medicinal product for treating patients with CD33-positive relapsed acute myeloid leukemia. The compound represents a novel anticancer therapy and has shown promising results in clinical trials.
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
A new experimental compound, CMA-676, demonstrates promising efficacy in treating acute myelogenous leukemia (AML) with an antibody-targeted chemotherapy approach. The treatment shows a remission rate of approximately 40% comparable to standard combination chemotherapy regimens.
A 15-year study of 628 AML patients confirms that chromosomal abnormalities can predict treatment success and likelihood of cure. Patients with specific genetic markers tend to have better outcomes, while those without them face poorer survival rates.
Researchers discovered a genetic defect in ALL1 gene duplication that signals poor prognosis and shorter survival time in AML patients. Patients with this defect require aggressive treatment, including allogenic bone marrow transplant, to improve survival rates.
SourceOhio State University·JournalCancer Research·DateJan 28, 1998
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.